Varonis (NASDAQ:VRNS) Surprises With Q1 Sales
Data protection and security software company Varonis (NASDAQ:VRNS) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 19.6% year on year to $136.4 million. The company expects next quarter's revenue to be around $147.5 million, close to analysts' estimates. Its non-GAAP profit of $0.01 per share was significantly above analysts' consensus estimates.
Is now the time to buy Varonis? Find out in our full research report.
Varonis (VRNS) Q1 CY2025 Highlights:
Revenue: $136.4 million vs analyst estimates of $133.4 million (19.6% year-on-year growth, 2.3% beat)
Adjusted EPS: $0.01 vs analyst estimates of -$0.05 (significant beat)
Adjusted Operating Income: -$6.5 million vs analyst estimates of -$11.98 million (-4.8% margin, 45.7% beat)
The company reconfirmed its revenue guidance for the full year of $617.5 million at the midpoint
Management raised its full-year Adjusted EPS guidance to $0.16 at the midpoint, a 3.3% increase
Operating Margin: -32.1%, up from -41.8% in the same quarter last year
Free Cash Flow Margin: 47.9%, up from 12.6% in the previous quarter
Annual Recurring Revenue: $664.3 million at quarter end, up 18.6% year on year
Billings: $142.4 million at quarter end, up 21.1% year on year
Market Capitalization: $4.91 billion
Yaki Faitelson, Varonis CEO, said, "Our first quarter results reflect the momentum of our SaaS platform as well as the many tailwinds that are contributing to the growth in our business, including MDDR and Generative AI. Our solution has never been more relevant, and we look forward to completing our SaaS transition this year which will unlock many more benefits for our customers and our company as we execute on our significant market opportunity.'
Company Overview
Founded by a duo of former Israeli Defense Forces cyber warfare engineers, Varonis (NASDAQ:VRNS) offers software-as-service that helps customers protect data from cyber threats and gain visibility into how enterprise data is being used.
Sales Growth
A company's long-term sales performance can indicate its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last three years, Varonis grew its sales at a 11.7% compounded annual growth rate. Although this growth is acceptable on an absolute basis, it fell short of our standards for the software sector, which enjoys a number of secular tailwinds.
Varonis Quarterly Revenue
This quarter, Varonis reported year-on-year revenue growth of 19.6%, and its $136.4 million of revenue exceeded Wall Street's estimates by 2.3%. Company management is currently guiding for a 13.2% year-on-year increase in sales next quarter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ('Gyre') (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A ('ETA') receptor antagonist, for the treatment of pulmonary arterial hypertension ('PAH').This milestone marks Gyre's entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China's National Rare Disease Catalog, underscoring its significance in public health. According to Frost & Sullivan, China's PAH market was valued at $370 million in 2023 and is projected to grow to $480 million by 2031.F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH Phase 1 trial is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The trial represents the latest expansion of Gyre's fibrosis-first strategy beyond the liver, leveraging a robust clinical development platform and commercial infrastructure in China.F230 joins Gyre's pipeline alongside lead candidate Hydronidone (F351), which met the primary endpoint in a pivotal Phase 3 trial for CHB-fibrosis. A New Drug Application ('NDA') submission to China's National Medical Products Administration ('NMPA') is planned for the third quarter of 2025, and a pre-IND meeting with the U.S. Food and Drug Administration is being planned for an expected Phase 2 trial in metabolic dysfunction-associated steatohepatitis ('MASH') Gyre TherapeuticsGyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre's strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People's Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning the expectations regarding Gyre's research and development efforts and timing of expected clinical trials, including an NDA submission to the NMPA for F351, the expected clinical benefits of F230 and expectations regarding interactions with regulators. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' 'plan' or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre's ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre's capital resources and its ability to raise additional capital. Additional risks and factors are identified under 'Risk Factors' in Gyre's Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC. Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by Contact:David ZhangGyre in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
39 minutes ago
- Business Wire
Leap and Xos Partner to Power the Grid with Electric Fleets
SAN FRANCISCO & LOS ANGELES--(BUSINESS WIRE)-- Leap, the leading platform for building and scaling virtual power plants (VPPs), and Xos, Inc., (NASDAQ:XOS), a leading electric truck manufacturer and fleet services provider, today announced a new partnership to unlock grid revenue opportunities for electrified fleets. By connecting Xos Hub charging technology to energy markets through Leap's automated platform, the companies will create new value for fleet owners and deliver crucial support for the grid during energy emergencies. By connecting Xos Hub charging technology to energy markets through Leap's automated platform, the companies will create new value for fleet owners and deliver crucial support for the grid during energy emergencies. Share Xos manufactures electric stepvan vehicles used by some of the country's most recognizable logistics companies, including FedEx and UPS. The company's Xos Hub is a mobile, battery-integrated charger designed to speed up fleet electrification without the delays or costs of traditional infrastructure. It provides a versatile, scalable solution for stopgap charging, remote deployments, semi-permanent charging, and backup power. Now, by using Leap's software-only VPP platform, Xos can enroll its customers in California's Demand Side Grid Support (DSGS) grid services program. During emergency grid events, participating fleets will automatically shift charging from the grid to their Xos Hub battery-integrating chargers, relieving grid strain while generating revenue. Last summer, with major contributions from Leap, DSGS helped California avoid blackouts during prolonged heatwaves. With the addition of Xos's rapidly growing portfolio, Leap and its partners are poised to scale their impact and deliver even greater support to the grid. 'Leveraging our complementary technologies, Leap and Xos are tapping new value streams for commercial truck fleets, the transportation services that power our economy,' said Jason Michaels, CEO of Leap. 'Together, we're making these fleets cleaner, smarter, and more cost effective, while contributing to a more resilient energy landscape.' Leap's universal API suite automates energy market operations, enabling Xos to quickly deploy and scale its own VPP offering without additional hardware or significant additional operational overhead. This means that Xos can immediately start generating new grid revenue, reducing the total product cost for customers and driving ongoing energy savings. 'Our VPP offering gives fleet customers advanced energy capabilities without compromising control or convenience,' said Dakota Semler, CEO of Xos, Inc. 'It's a powerful way to lower the cost of infrastructure ownership even further, maximize the value of our products, and support customers in meeting their electrification goals.' About Leap Leap is the leading platform for launching and scaling virtual power plants (VPPs). Through its software-only solution, Leap facilitates fast, easy and automated access to demand response and other grid services revenue streams for the providers of battery storage systems, EV chargers, smart building technologies, and other distributed energy resources (DERs). Managing over 200,000 energy sites and devices across U.S. energy markets, Leap empowers more than 90 technology partners and their customers to unlock new value and help create a more flexible, resilient grid powered by renewable resources. Visit to learn more. About Xos, Inc. Xos is a leading technology company, electric truck manufacturer, and fleet services provider for battery-electric fleets. Xos vehicles and fleet management software are purpose-built for medium- and heavy-duty commercial vehicles that travel on last-mile, back-to-base routes. The company leverages its proprietary technologies to provide commercial fleets with battery-electric vehicles that are easier to maintain and more cost-efficient on a total cost of ownership (TCO) basis than their internal combustion engine counterparts. For more information, visit
Yahoo
an hour ago
- Yahoo
Baird Cuts Tesla to Hold as Musk's Role, Robotaxi Hype Create Uncertainty
Tesla (NASDAQ:TSLA) just got a reality check from one of its long-time bulls. Robert W. Baird analyst Ben Kallo downgraded the stock from Buy to Hold his first such move in three years. While the firm is still sticking to its $320 price target, that's a slight drop from where Tesla's currently trading. In other words, Baird doesn't see much short-term upside right now. Why the shift? Kallo pointed to growing hype around Tesla's upcoming robotaxi event. He thinks expectations may be running a bit too hot, especially considering the company was only just added to Austin's autonomous vehicle testing registry. By comparison, Alphabet's (NASDAQ:GOOG) Waymo is already in the deployment phase. There's also what Kallo calls key-man risk. That's a reference to Elon Musk, whose influence at Tesla is massive. His recent public support for Donald Trump and involvement in political discourse is creating more uncertainty, not less at least from an investor perspective. Interestingly, Tesla shares were up about 3% in premarket trading. That may reflect cooling tensions between Musk and Trump, with reports that the president plans to keep his Tesla and Starlink setup if he returns to the White House. Kallo still sees Tesla as a long-term player, but for now, he's urging caution. Other factors like tougher EV competition, shifting delivery estimates, and possible changes to tax incentives are also in the mix. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
